Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
|
|
- Kristian Stephens
- 6 years ago
- Views:
Transcription
1 Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori Polmonari IRCCS Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro Genova
2 Bevacizumab and NSCLC: starving the enemy to survive Angiogenesis is the process of new blood vessel formation Angiogenesis is required for tumours to grow and metastasize Tumours generally cannot grow beyond 1 2 mm in diameter without an independent blood supply 1,2 Therefore, angiogenesis is an important process in the growth of malignant tumours Avascular tumour Vascularised tumour Growth factors e.g. VEGF Grossi F, Expert Opin Biol Ther 2007
3 Agenda Bevacizumab + CT in first-line: efficacy Bevacizumab + CT in first-line: safety Bevacizumab + CT in first-line: future perspectives
4 Agenda Bevacizumab + CT in first-line: efficacy Bevacizumab + CT in first-line: safety Bevacizumab + CT in first-line: future perspectives
5 E4599: trial design Trial commenced 2001 Previously untreated stage IIIB, IV or recurrent predominantly nonsquamous NSCLC (n=878) R 1 1 CP q3w x6 (n=444) Bevacizumab 15mg/kg + CP q3w x6 (n=434) Bevacizumab to progression PD* PD Primary endpoint overall survival (OS) *No crossover permitted; CP = carboplatin/paclitaxel Secondary endpoints objective response rate progression-free survival (PFS) duration of response safety Sandler A, NEJM 2006
6 Bevacizumab-based therapy until progression increases OS: E4599 Sandler A, NEJM 2006
7 E4599: pre-planned OS analysis in adenocarcinoma subgroup Sandler A, JTO 2010 & NEJM 2006
8 Algorithm for therapy of advanced NSCLC Proposed treatment algorithm EGFR mutation positive or ALK fusion positive Molecular Good PS Clinical (PS) Poor PS EGFR TKIs or Crizotinib Nonsquamous Histologic Squamous Single-agent chemotherapy Bevacizumab eligible Clinical Bevacizumab ineligible First line Platinum/pemetrexed (or other*) ± bevacizumab Platinum/pemetrexed (or other*) Platinum/gemcitabine (or other*) Progression Chemotherapy by algorithm Bevacizumab or erlotinib or pemetrexed Based on prior therapy End of first-line chemotherapy Pemetrexed or erlotinib Based on prior therapy Erlotinib Based on prior therapy Based on prior therapy Maintenance Second line *Docetaxel, paclitaxel, or vinorelbine. Adapted from Gandara DR, Clin Lung Cancer 2009
9 AVAiL: Study design 6 cycles Previously untreated stage IIIB/IV nonsquamous NSCLC (n=1043) R 2:1:1:2 Bevacizumab 15 mg/kg q3w + cisplatin + gemcitabine (n=351) Placebo 15 mg/kg a + cisplatin + gemcitabine (n=347) Placebo 7.5 mg/kg a + cisplatin + gemcitabine Bevacizumab 7.5 mg/kg q3w + cisplatin + gemcitabine (n=345) Bevacizumab 15 mg/kg q3w Placebo 15 mg/kg a Placebo 7.5 mg/kg a Bevacizumab 7.5 mg/kg q3w Treat to PD Primary endpoint: PFS Secondary endpoints: ORR, DoR, OS, safety Stratification factors: Region, disease stage, ECOG PS, sex a No crossover to bevacizumab permitted Reck M, JCO 2009
10 AVAiL: significant prolongation of PFS (primary endpoint) Reck M, JCO 2009
11 AVAiL: no significant benefit in OS* (secondary endpoint) Reck M, Ann Oncol 2010 *ITT (intent-to-treat) population
12 AVAiL: high proportion of patients received post-protocol therapies Post-protocol therapy* Placebo + CG % (n) Bev 7.5mg/kg + CG % (n) Bev 15mg/kg + CG % (n) Any treatment, % (n) 65 (224) 61 (210) 61 (214) Treatment/procedures, % (n) TKIs 41 (92) 48 (100) 42 (90) Chemotherapy 73 (164) 65 (137) 69 (147) Angiogenesis inhibitors <1 (2) <1 (2) <1 (3) Surgical and medical procedures 26 (60) 34 (71) 27 (57) *Total patients with 1 treatment % patients who received a post-protocol therapy Includes but not limited to radiotherapy, laser therapy and stent placement Reck M, Ann Oncol 2010
13 OS estimate AVAiL: improved OS in bevacizumab pts not receiving post-protocol therapies* Median OS (95% CI) No 2nd-line Bev 8.7 ( ) Placebo 7.3 ( ) 0.6 HR (p value) Bev to placebo 0.84 (0.20) Bev without 2nd-line Placebo without 2nd-line n=123 n= *Exploratory analysis Time (months) Reck M, Ann Oncol 2010
14 Meta-analysis of beva+ct vs CT in advanced NSCLC: OS and PFS OS PFS Costa Lima BC, PLOS ONE 2011
15 SAiL: trial design Trial commenced 2006 First-line, advanced non-squamous NSCLC (n=2,212) Bevacizumab 7.5mg/kg or 15mg/kg q3w + standard of care chemotherapy x6 Bevacizumab to progression PD Primary endpoint safety profile Secondary endpoints time to disease progression (TTP) overall survival safety in CNS metastases Crinò L, Lancet Oncol 2010
16 OS estimate SAiL: Efficacy consistent with phase III data Bev + any chemotherapy (SAiL ITT population)* Bev + CP (E4599 adenocarcinoma analysis) CP (E4599 adenocarcinoma analysis) Time (months) *86% of patients in SAiL had adenocarcinoma histology Crinò L, Lancet Oncol 2010 Crinò, et al. Lancet Oncol 2010; Sandler, et al. JTO 2010
17 Median OS (months) SAiL: Consistent efficacy across all chemotherapy backbones n=2,212 Overall SAiL population n=1,087 n=829 Bevacizumab + carboplatin doublets Bevacizumab + cisplatin doublets Data for other groups (total n=296, including non-platinum doublets, single-agent chemotherapy and other chemotherapy combinations) are not statistically robust due to small patient numbers and are not reported Crinò, et al. Lancet Oncol 2010 Crinò L, Lancet Oncol 2010
18 ARIES: Avastin Registry: Investigation of Effectiveness and Safety Registry with 2000 first-line patients Bevacizumab combined with any standard of care chemotherapy Bevacizumab continued at physician s discretion Stage IIIB/IV non-squamous NSCLC (n 2,000) Bevacizumab (7.5 or 15 mg/kg) q3w + chemotherapy* Bevacizumab continued at physician s discretion Objectives: Safety and effectiveness of becvacizumab *Any standard-of-care first-line NSCLC chemotherapy Wozniak A, ASCO 2010
19 Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG): Study design First-line, advanced non-squamous NSCLC (n= 314) Bevacizumab (15 mg/kg) q3w + standard of care chemotherapy PD Primary endpoint safety profile Secondary endpoints ORR PFS overall survival (OS) safety in pts with CNS metastases. Matikas A, Cancer Chemother Pharmacol 2016
20 Efficacy: PFS and OS mpfs=7.7 mesi mos=17.6 mesi Matikas A, Cancer Chemother Pharmacol 2016
21 Median OS (months) Efficacy of first-line regimens: pre-planned OS analyses in adenocarcinoma patients 18 Cisplatin + pem (JMDB) 1 HR=0.84 Bevacizumab-based therapy (E4599) 2 HR= CG Cis/pem 1. Scagliotti G, Oncologist Sandler A, JTO 2010 CP Cross-trial comparisons should be interpreted with caution Bevacizumab + CP
22 Median PFS (months) Efficacy of first-line regimens: pre-planned PFS analyses in adenocarcinoma patients 18 Cisplatin + pem (JMDB) 1 HR=0.90 Bevacizumab-based therapy (E4599) 2 HR= CG Cis/pem 1. Scagliotti G, Oncologist Sandler A, JTO 2010 CP Cross-trial comparisons should be interpreted with caution Bevacizumab + CP
23 PRONOUNCE: Study Design Randomized, open-label, phase III superiority study conducted in US Pemetrexed 500 mg/m 2, Carboplatin AUC 6 (Pem+Cb) Paclitaxel 200 mg/m 2, Carboplatin AUC 6, Bevacizumab 15 mg/kg (Pac+Cb+Bev) Induction Phase q21d, 4 cycles Maintenance Phase q21d until PD Bev-Eligible Population Inclusion: - Chemo-naïve patients - PS 0/1 - Stage IV, nonsquam - Stable treated CNS mets Exclusion: - Uncontrolled effusions Stratified for: R 1:1 Pemetrexed (folic acid & vitamin B 12 ) + Carboplatin 180 patients each Paclitaxel + Carboplatin + Bevacizumab PS (0 vs 1); gender (M vs F); disease stage (M1a vs M1b) Pemetrexed (folic acid & vitamin B 12 ) Bevacizumab Zinner RG, JTO 2015
24 PRONOUNCE: primary objective Progression free survival without grade 4 AE (assuming HR of 0.75, there was 80% power to detect superiority of CBDCA+Pem over CBDCA+PAC+Bev with a 2-sided type I error of 0.10) Secondary objective: OS, PFS, RR, DCR, safety and tolerability Zinner RG, JTO 2015
25 PRONOUNCE: secondary endpoints (PFS, RR, DCR) Zinner RG, JTO 2015
26 PRONOUNCE: overall survival Zinner RG, JTO 2015
27 PRONOUNCE: secondary endpoints (toxicity) Zinner RG, JTO 2015
28 Agenda Bevacizumab + CT in first-line: efficacy Bevacizumab + CT in first-line: safety Bevacizumab + CT in first-line: future perspectives
29 Consensus on bevacizumab safety Exclusion factors for bevacizumab Squamous histology Haemoptysis grade 2 Invalid exclusion factors Central tumour location Cavitation Full-dose anticoagulation Elderly Major vessel invasion = individual assessment No clinical or radiological features (including cavitation and central tumour location) have been shown to be reliable predictive factors for severe PH in bevacizumab-treated patients. Major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting, may predict PH. However, standardized radiological criteria for defining infiltration have not been established. Reck M, Ann Oncol 2011
30 Patients (%) Bevacizumab has a wellestablished safety profile 30 Grade 3 AEs of special interest E (15mg/kg) AVAiL 2 (7.5mg/kg) AVAiL 2 (15mg/kg) 20 SAiL 3 ARIES , ,6 3,6 1,9 1,5 0,9 0,7 0, ,7 <5.0 Bleeding Pulmonary Hypertension Proteinuria (all types) haemorrhage 3.0 < ,1 NR 1. Sandler A, NEJM 2006; 2. Reck M, Ann Oncol Crinó L, Lancet Oncol 2010; 4. Wozniak A, ASCO 2010
31 Meta-analysis of beva+ct vs CT in advanced NSCLC: gr. 3-4 toxicities Costa Lima BC, PLOS ONE 2011
32 Agenda Bevacizumab + CT in first-line: efficacy Bevacizumab + CT in first-line: safety Bevacizumab + CT in first-line: future perspectives
33 OS estimate PFS estimate Continued VEGF suppression leads to improved clinical outcomes in NSCLC pts Retrospective analysis of electronic medical records of NSCLC patients (n=403) from community-based oncologists network in the USA 1.0 continued bevacizumab leads to more favourable clinical outcomes Bevacizumab to progression No bevacizumab to progression Months Months Nadler E, The Oncologist 2011
34 Bevacizumab to progression: SAiL experience SAiL methodology directed continuing bevacizumab until disease progression consistent with global product label maintaining precise inhibition of continuously expressed VEGF In SAiL, 1332 patients achieved disease control and continued to receive bevacizumab until disease progression Dansin, ESMO 2010
35 Median OS (months) 18.8 months median OS achieved in responding patients treated to progression Dansin, ESMO 2010 n=2,212 Total study population n=1,332 Bevacizumab continued to PD in responding patients (CR/PR/SD)
36 SAiL: continuing bevacizumab to progression has limited impact on safety profile No maintenance population (n=880) Maintenance population (n=1,332) Patients (%) Grade 3 Grade 3 Overall bleeding Epistaxis PH/haemoptysis CNS bleeding HTN Proteinuria Thromboembolism Cerebral haemorrhage/haematoma Dansin, ESMO 2010
37 Randomize 1:1 AvaALL: trial design Global trial conducted in ~20 countries Primary endpoint: OS Stage IIIB/IV non-squamous NSCLC treated with platinumdoublet (4-6 cycles) + bevacizumab PLUS > 2 cycles of bevacizumab maintenance N=600 PD 1 Enroll SOC2* + bevacizumab PD 2 SOC3 + bevacizumab PD 3 SOC4 ± bevacizumab SOC2* SOC3 SOC4 * SOC2: Labelled agents for 2 nd -line treatment of NSCLC (erlotinib, pemetrexed and docetaxel) SOC3 and beyond: Choice of labelled agents in 3 rd -line and beyond is the Investigator s choice Bevacizumab dose must remain the same throughout the trial Beyond PD3, bevacizumab should be continued through subsequent lines of therapy at Investigator s discretion (in the absence of unacceptable toxicity or consent withdrawal)
38 AVAPERL1: phase III trial of bevacizumab ± pemetrexed maintenance AVAPERL1 trial design Previously untreated stage IIIB/IV nonsquamous NSCLC (N>400) Bevacizumab 7.5 mg/kg + Pemetrexed/Cisplatin q3w Bevacizumab 7.5 mg/kg + Pemetrexed q3w Bevacizumab 7.5 mg/kg q3w PD PD Induction: 4 cycles Maintenance therapy Primary objective: PFS Secondary objectives: OS, ORR, disease control rate, duration of response, duration of disease control, safety, QoL Barlesi F, ESMO 2011
39 Cisplatin + pemetrexed maintenance AVAPERL: PFS from induction Barlesi F, ESMO 2011
40 PointBreak: study design Randomized, open-label, phase III superiority study conducted in US Pemetrexed 500 mg/m 2 ; Carboplatin AUC 6; Bevacizumab 15 mg/kg Paclitaxel 200 mg/m 2 ; Carboplatin AUC 6; Bevacizumab 15 mg/kg Inclusion: - No prior systemic therapy for lung cancer - PS 0/1 - Stage IIIB-IV NS-NSCLC - Stable tx t brain mets Exclusion: - Peripheral neuropathy > Gr 1 - Uncontrolled pleural effusions R 1:1 Induction Phase q21d, 4 cycles Pemetrexed (folic acid & vitamin B 12 ) + Carboplatin + Bevacizumab 450 patients each Paclitaxel + Carboplatin + Bevacizumab Maintenance Phase q21d until PD Pemetrexed (folic acid & vitamin B 12 ) + Bevacizumab Bevacizumab Stratified for: PS (0 vs 1); sex (M vs F); disease stage (IIIB vs IV); measurable vs nonmeasurable disease Patel JD, CMLCC 2012
41 PointBreak: PFS and OS from randomization (ITT) Patel JD, CMLCC 2012
42 Examples of phase III anti-pd1/pd-l1 combination trials in 1 st -line advanced NSCLC
43 Phase 3 and 4 trials of bevacizumab at the first-line setting of NSCLC Matikas A, Cancer Chemother Pharmacol 2016
44 Grazie per l attenzione! francesco.grossi@hsanmartino.it
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationAngiogenesi nel NSCLC: stato dell arte
Angiogenesi nel NSCLC: stato dell arte Andrea Camerini Oncologia Medica - Ospedale Versilia Investigator Meeting Study GOIRC Overview Neoangiogenesis in NSCLC (among others) Lots of targets lots of drugs
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More information2012 Chicago Multidisciplinary Symposium in Thoracic Oncology September 6-8, 2012 Friday, September 7, News Briefing 7:15 a.m.
2012 Chicago Multidisciplinary Symposium in Thoracic Oncology September 6-8, 2012 Friday, September 7, News Briefing 7:15 a.m. Central time Moderated by Heather Wakelee, MD Stanford University Stanford,
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationBevacizumab treatment for advanced non small cell lung cancer: A case report
ONCOLOGY LETTERS 6: 1779-1783, 2013 Bevacizumab treatment for advanced non small cell lung cancer: A case report YUN FAN *, ZHIYU HUANG and WEIMIN MAO * Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationAntiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño
Antiangiogénesis Sigue siendo una alternativa? Javier de Castro Carpeño Formigal, 24 de junio de 2016 Antiangiogénesis Sigue siendo una alternativa? Angiogenesis: A hallmark of cancer leading to malignant
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationSystemic Management of Malignant Pleural Mesothelioma
ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 15.June-19.June 2018 Belgrade, Serbia Systemic Management of Malignant Pleural Mesothelioma Dragana Jovanovic University Hospital
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pembrolizumab (Keytruda) for Nonsquamous Non-small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationLung cancer is the leading cause of cancer-related death in the
ORIGINAL ARTICLE Bevacizumab Maintenance in Patients with Advanced Non Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study Results of An Exploratory
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationSequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER Strategic Approaches Sequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI Yi-Long Wu Guangdong
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationLung cancer imposes a considerable public health and
ORIGINAL ARTICLE Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC Results from the Phase IV MO19390 (SAiL) Study Chun-Ming Tsai, MD,* Joseph
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationAggiornamenti in oncologia tra ricerca e clinica: Carcinoma del polmone
Convegno Interregionale AIOM Lombardia, Liguria, Piemonte e Valle D Aosta Coniugare innovazione, sostenibilità e continuità di cura in oncologia: il ruolo delle Reti regionali Milano, 19 Novembre 2016
More information